NEW YORK (GenomeWeb News) – Bruker Biosciences today reported that total revenues for the second quarter increased nearly 10 percent as net income jumped 69 percent.
The report caused shares in Bruker to trade up 6 percent, or $.35, at $5.86 in mid-afternoon trading.
Receipts for the three months ended June 30 increased to $78 million from $71 million year over year.
R&D costs declined 3 percent to $10.6 million from $11 million from the comparable quarter a year ago.
The company said net income increased to $480,000 from $284,000 during the comparable period last year.
Bruker said it had around $96.6 million in cash and cash equivalents as of June 30.